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Background: Chronic inflammation is one of the important mediators of colitis-
related colon cancer (CRC). Abundant mast cells (MCs) were observed in the tumor
microenvironment and mediators released upon MC activation play an important role
in the process of chronic inflammation. Previously, we found that activation of intestine
mucosal MCs recruited and modulated the inflammatory CD11b+Gr1+ cells to promote
the CRC development. In the current study we investigated the effects of Vam3, a
resveratrol dimer with potent anti-inflammatory effects, on CRC development.
Methods: RBL-2H3 cells, a basophilic leukemia cell line, were pretreated with 2.5 or
5 µM Vam3 and then stimulated with dinitrophenol-conjugated bovine serum albumin
(DNP-BSA) plus lipopolysaccharide (LPS). The MC degranulation was determined by
measuring β-hexosaminidase release. Generation of TNF-α and IL-6 in RBL-2H3 cells
or in peritoneal macrophages was determined by ELISA and real-time qPCR. NF-κB
p65 and phospho-NF-κB p65 expression was determined by Western blotting. NF-
κB activity in RAW264.7 cells was determined by luciferase reporter assay. CRC was
induced in C57BL/6 mice by intraperitoneal injection of azoxymethane (AOM), followed
by oral exposure to dextran sodium sulfate (DSS). Vam3 at 50 mg/kg, or disodium
cromoglycate (DSCG, MC stabilizer) at 100 mg/kg, or vehicle were administrated to the
mice 4 weeks after DSS withdrawal. Levels of TNF-α, IL-6, and mouse MC protease-1
were determined by ELISA. Infiltration of CD11b+Gr1+ cells was determined by flow
cytometry analysis. One-way ANOVA was used to compare difference between groups.
Results: Pretreatment with Vam3 significantly inhibited RBL-2H3 cell degranulation
and inflammatory cytokine production from RBL-2H3 cells and from peritoneal
macrophages. After Vam3 treatment, NF-κB activity in RAW264.7 cells, and expressions
of phospho-NF-κB p65 in RBL-2H3 cells and in peritoneal macrophages were
significantly down-regulated. In the AOM plus DSS-induced CRC murine model, the
Vam3 and DSCG-treated mice had less tumor numbers than those treated with
vehicle. Expression of phospho-NF-κB p65, production of inflammatory cytokines, and
infiltration of MCs and CD11b+Gr1+ cells were attenuated in the Vam3-treated mice.
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Conclusion: Vam3 treatment could attenuate the CRC development. This effect may
be due to its inhibition on NF-κB signaling pathway in MCs and macrophages of the
inflamed intestines.
Keywords: natural compounds, colitis-related colon cancer, inflammation, mast cells, CD11b+Gr1+ cells, NF-κB
INTRODUCTION
Intrinsic genetic lesion is critical in tumor formation,
nevertheless, the importance of chronic inflammation in
cancer development has been highlighted recently (Thompson
et al., 2015; Romano et al., 2016). Epidemiological and clinical
evidences have pointed out that chronic inflammation is one of
the most important players in colorectal cancer development
(Kraus and Arber, 2009). It was reported that the cumulative
incidence of colon cancer in patients with chronic inflammatory
bowel disease (IBD) increased to 2, 8, and 20% at 10, 20, and
30 years of disease (Eaden et al., 2001). Anti-inflammatory drugs,
such as aspirin, celecoxib, and ibuprofen, have been shown to
reduce the incidence of cancer when used as prophylactics,
particularly in colon cancer (Harris et al., 2005; Friis et al.,
2015). Moreover, the active ingredients of traditional Chinese
medicine have gained increasing attention to their applications
in the prevention of inflammation-associated cancer risk.
Glycyrrhizic acid, a natural and major pentacyclic triterpenoid
glycoside of licorice roots extracts, inhibits the development
of colon precancerous lesion via regulating the inflammation,
hyperproliferation, angiogenesis and apoptosis in the colon of
Wistar rats (Khan et al., 2013; Huang et al., 2016). Thus, agents
that attenuate intestinal inflammation might be helpful for the
prevention of colitis-related colon cancer (CRC).
As the important sentinel cells to the inflammatory stimuli,
the role of mast cells (MCs) in promoting the CRC development
has been identified in recent years (Gounaris et al., 2007; Khazaie
et al., 2011; Tanaka and Ishikawa, 2013; Chen et al., 2015).
Based on their morphology, contents of protease, chemistry,
and location, MCs are generally divided into two distinct
types: mucosal MCs and connective tissue MCs (Gurish and
Austen, 2012). In the intestine, mucosal MCs preferentially
reside in the epithelium and the lamina propria and express the
chymases mouse MC protease (mMCP)-1 and mMCP-2, whereas
connective tissue MCs reside in the submucosa and express the
chymases mMCP-4 and mMCP-5, and the tryptases mMCP-6,
mMCP-7, and carboxypeptidase A (CPA) (Kalesnikoff and Galli,
2008; Khazaie et al., 2011). Mucosal MCs appear to dominate at
the site of newly developing polyps, while connective tissue MCs
are more prevalent in the stroma at later stages of invasive tumor
(Maltby et al., 2009). Gounaris et al. (2007) showed that MCs
were the causative agents in polyp formation, the initiating step
of colon cancer. Colombo and Pucillo and their colleges reported
that MCs were able to counteract the Treg inhibition over effector
T cells to play a key role in the inflammation development
(Piconese et al., 2009). Furthermore, they demonstrated that
MCs boost the activity of myeloid-derived suppressor cells
(MDSCs) and contribute to the development of tumor-favoring
microenvironment (Danelli et al., 2015a). Previously, we found
that activation of intestine mucosal MCs recruited and modulated
the inflammatory MDSCs to promote the CRC development
(Xu et al., 2015). As their importance as an early source of
the inflammatory mediators, MCs, especially the mucosal MCs
might be the potential therapeutic targets for preventing CRC
development.
Lipopolysaccharide (LPS)/Toll-like receptor-4 (TLR4)/NF-κB
pathway plays a crucial role in the development of CRC (Tye and
Jenkins, 2013). TLR4 is expressed in many cells, including colonic
epithelial cells and the underlying lamina propria immune cells,
such as macrophages (Abreu, 2010). Using a colitis-associated
cancer model, Fukata et al. (2009) showed that deletion of
TLR4 in intestinal epithelial cells could attenuate formation
of inflammation-associated tumors. However, mice with TLR4
expression only in the myeloid cells still develop tumors. TLR4
signal from myeloid cells also contribute to some extent to
the development of colitis-associated neoplasia (Fukata et al.,
2009). TLR4/MyD88 signaling in myeloid cells has been shown
to support spontaneous colon cancer development (Grivennikov
et al., 2012). Moreover, Greten et al. (2004) showed that deleting
IκB kinase (IKK) in myeloid cells resulted in a significant decrease
in tumor size. Therefore, it is most likely that LPS/TLR4/NF-
κB signaling in both non-immune (epithelial) and immune
(myeloid) cell types contribute to the development of colon
cancer. Targetting the LPS/TLR4/NF-κB signaling pathway with
inhibitors may hold promises in treating colon cancer.
Natural compounds derived from herbal medicine have
been reported to have a wide range of biological activities
(Newman and Cragg, 2012; Ding et al., 2014). Resveratrol, a
polyphenolic compound found in grapes and wine, was reported
to possess several beneficial biological effects, including anti-
oxidant and anti-inflammatory effects (Yang et al., 2015; Conti
et al., 2016; Diaz-Gerevini et al., 2016). Several studies suggest
that the chemopreventive effects of resveratrol are partially due to
epigenetic regulation and post-transcriptional modifications on
the targeted tumor cells (Ross et al., 2008; Saud et al., 2014; Kumar
et al., 2015). Recently, studies showed that resveratrol could
prevent tumorigenesis in mouse model of Kras activated sporadic
colorectal cancer by suppressing oncogenic Kras expression
(Saud et al., 2014). Vam3 is a resveratrol dimer derived from
Vitis amurensis Rupr., which grows in northeastern and central
China. Previously we found that Vam3 possessed potent anti-
inflammatory and anti-oxidant effects (Shi et al., 2012; Xuan
et al., 2014) and was able to inhibit airway inflammation in some
animal models (Li et al., 2006; Yang et al., 2010). Vam3 could
inhibit macrophages and MCs-mediated inflammatory response
(Li et al., 2006; Cao et al., 2014). In the present study, we
reported that Vam3 could inhibit RBL-2H3 cell degranulation
and decrease cytokine production in RBL-2H3 cells and in
peritoneal macrophages. Pretreatment with Vam3 inhibited CRC
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development in an azoxymethane (AOM) plus dextran sodium
sulfate (DSS)-induced CRC murine model. MC infiltration and
degranulation, cytokine release and CD11b+Gr1+ infiltration
were attenuated by Vam3 treatment.
MATERIALS AND METHODS
Materials
Compound Vam3, synthesized from resveratrol, was provided by
the Institute of Materia Medica, Chinese Academy of Medical
Sciences (Beijing, China; Huang et al., 1999). The purity of Vam3
was above 98% as determined by 1H-NMR spectra. Rat basophilic
leukemia cell lines (RBL-2H3) and murine macrophage cell
lines (RAW264.7) were obtained from the American Type
Culture Collection (ATCC, Rockville, MD, USA). LPS (serotype
O127:B8), AOM, disodium cromoglycate (DSCG), dinitrophenol
(DNP)-specific IgE, and DNP-conjugated bovine serum albumin
(DNP-BSA) were purchased from Sigma–Aldrich (St. Louis, MO,
USA). DSS (MW = 36,000–50,000) was purchased from MP
Biomedicals, LLC (Solon, OH, USA). FITC-conjugated anti-
mouse CD45 antibodies, PE.Cy7-conjugated anti-mouse CD11b
antibodies, and APC-conjugated anti-mouse Gr1 antibodies
were purchased from eBioscience (San Diego, CA, USA).
Recombinant mMCP-1 was purchased from Sino Biological
Inc. (Beijing, China). Anti-CD117 antibody was purchased
from Dako (Carpinteria, CA, USA). FuGENE HD Transfection
Reagent was purchased from Promega (Madison, WI, USA).
Anti-phospho-NF-κB p65 (Ser536) antibodies, anti-NF-κB p65
antibodies, and anti-β-actin antibodies were purchased from Cell
Signaling Technology (Beverly, MA, USA).
Isolation of Peritoneal Macrophages
Primary peritoneal macrophages are used for various in vitro
studies. However, the yield is typically only ∼0.5–1 × 106
macrophages per mouse. Injecting thioglycollate into peritoneum
can increase the yield and purity of macrophages (Zhang et al.,
2008).
Peritoneal macrophages were isolated according to the
reference (Zhang et al., 2008). Briefly, the male C57BL/6 mice
received 1.5 mL of 3% thioglycollate medium via intraperitoneal
injection. Four days later, 5 mL ice-cold PBS were injected into
the peritoneal cavity. The abdominal cavity was massaged to
dislodge loosely adherent peritoneal cells, and the lavage was
obtained by recovering of the injected PBS. The procedure was
repeated twice for each mouse. The peritoneal lavage fluid was
centrifuged at 500× g for 5 min. The cell pellet was washed with
ice-cold RPMI-1640 medium containing 1% fetal bovine serum
(FBS). The cells were then cultured at 37◦C in an air atmosphere
containing 5% CO2 for 2 h. The non-adherent cells were removed
by washing with warmed PBS.
Cell Viability Assay
RBL-2H3 and RAW264.7 cells were grown in Dulbecco’s
Modified Eagle Medium (DMEM) supplemented with 10%
FBS. Peritoneal macrophages isolated as described above were
grown in RPMI-1640 medium containing 10% FBS. Cell
viability was assessed using the MTT assay. RBL-2H3, peritoneal
macrophages, and RAW264.7 were plated into 96-well plates at
a density of 1 × 104 cells per well. Following overnight culture,
the cells were then treated with Vam3 (0, 1, 2.5, 5, or 10 µM)
for 12, 24, 36, or 48 h. The same volume of DMSO was added
to control wells. The cells were subsequently incubated in fresh
medium containing MTT solution (0.5 mg/mL) for 4 h at 37◦C.
The culture medium was removed, and the formazan dye was
dissolved in DMSO. The optical densities (OD) at 570 nm were
measured with a microplate reader. Relative cell viability was
expressed as percentage of controls that were cultured in the
absence of Vam3.
β-Hexosaminidase (β-HEX) Release
Assay
RBL-2H3 cells, a rat basophilic leukemia cell line that was widely
used in MC-associated studies (Passante and Frankish, 2009),
were plated into 96-well plates at a density of 1 × 104 cells per
well and sensitized with 0.1 µg/mL DNP-specific IgE for 24 h.
The cells were then treated with Vam3 (0, 2.5, or 5 µM) for 2 h
followed by adding 1 µg/mL LPS for 48 h. The same volume
of DMSO was added to control wells. To test degranulation, the
cells were stimulated with 500 ng/mL DNP-BSA for 30 min. Fifty
microliters of cell culture supernatant or cell lysates (lysed with
0.5% Triton X-100 to measure residual cell-associated β-HEX)
were mixed with an equal volume of substrate solution (2 mM
p-nitrophenyl-N-acetyl-β-D-glucosaminide dissolved in 0.1 M
sodium citrate buffer, pH 4.5) and incubated for 1 h at 37◦C.
The enzyme reaction was terminated by adding 200 µL of stop
solution (0.1 M Na2CO3/NaHCO3, pH 10.0), and the absorbance
was measured at 405 nm with a microplate reader. Release
of β-HEX was calculated as a percentage of β-HEX release in
the culture medium to the whole β-HEX release in the culture
medium and in the cell lysate.
Quantification of TNF-α and IL-6 in
RBL-2H3 Cells and in Peritoneal
Macrophages
RBL-2H3 cells (3 × 104/well) and peritoneal macrophages
(5 × 105 cells/well) were pretreated with Vam3 (0, 2.5, or 5 µM)
for 2 h followed by stimulating with 1 µg/mL LPS for 6 h
(for RNA analysis) or for 24 h (for protein analysis). The same
volume of DMSO was added to control wells. Total RNA was
extracted using TRIzol. First-strand cDNA was synthesized using
Prime Script RT Reagent kit (Takara Bio, Otsu, Japan). Real-
time qPCR was performed using SYBR Premix Ex Taq (Takara
Bio, Otsu, Japan). Primers used for real-time qPCR (Table 1)
was purchased from SinoGenoMax (Beijing, China). The relative
mRNA levels of TNF-α and IL-6 were determined with β-actin
or GAPDH as the control and represented as 2−11Ct. The cell
culture supernatant TNF-α and IL-6 levels were determined using
ELISA kits (eBioscience, San Diego, CA, USA).
NF-κB Luciferase Reporter Assay
Murine macrophage RAW264.7 cells were plated in 48-well plates
at 1 × 105 cells/well and transfected with NF-κB luciferase
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TABLE 1 | List of Primers Used for Real-Time qPCR.
Genes Forward primer (5′–3′) Reverse primer (5′–3′)
Murine TNF-α TGTCCCTTTCACTCAC
TGGC
CATCTTTTGGGGGAGT
GCCT
Murine IL-6 GGGACTGATGCTGGTG
ACAA
TCCACGATTTCCCAGAG
AACA
Murine GAPDH CTCCCACTCTTCCACC
TTCG
TAGGGCCTCTCTTGC
TCAGT
Rat TNF-α CGGGCTCAGAATTTCC
AACA
CGCAATCCAGGCCACT
ACTT
Rat β-actin GGAGATTACTGCCCCTG
GCTCCTA
GACTCATCGTACTCCTGC
TTGCTG
plasmid using FuGENE HD Transfection Reagent. Twenty-four
hours later, the cells were pretreated with Vam3 (0, 2.5, or 5 µM)
for 2 h and then stimulated with 1 µg/mL LPS for 24 h. The
same volume of DMSO was added to control wells. The cells were
lysed with 1x passive lysis buffer. Luciferase activity was measured
using the luciferase assay kit (Promega, Madison, WI, USA).
Quantification of NF-κB Subunit
Expression
RBL-2H3 cells and peritoneal macrophages were pretreated with
Vam3 (0, 2.5, or 5 µM) for 2 h followed by stimulating with
1 µg/mL LPS for 12 h. The same volume of DMSO was added to
control wells. Total protein was extracted using protein extraction
kit (Tiangen Biotech, Beijing, China). NF-κB p65 and phospho-
NF-κB p65 expression was examined by Western blotting. The
density of each band was quantified by QuantiScan Version 11
(Biosoft, Cambridge, UK). Densities of NF-κB p65 and phospho-
NF-κB p65 bands were normalized against β-actin.
Induction of CRC and Treatment with
Vam3
Colitis-related colon cancer was induced as previously report
(Okayasu et al., 1996). Male C57BL/6, 8–10 weeks, were
purchased from the Institute of Laboratory Animal Sciences,
Chinese Academy of Medical Sciences (CAMS, Beijing, China).
12.5 mg AOM was dissolved in 5 mL normal saline and
injected intraperitoneally at 12.5 mg/kg body weight (5 µL/g
body weight). One week later, the mice were exposed orally
to 2.5% DSS (MW = 36,000–50,000) for 5 days. Then fresh
water was replaced without further treatment. Four weeks after
DSS withdrawal, the mice were randomly divided into three
groups. One group of the mice (n = 9) received DSCG (Oka
et al., 2012; Xu et al., 2015) daily at 100 mg/kg of body weight,
one group (n = 9) received Vam3 daily at 50 mg/kg of body
weight, and one group (n = 9) were treated with vehicle
control (0.1% Tween 80 in distilled water). All the reagents
were administrated by gavage for 2 weeks. Mice were sacrificed
by CO2 asphyxiation 8 weeks after completing the treatment
and the colon tissues were collected. Each colon was opened
longitudinally and any fecal contents were cleared out with ice-
cold saline. The colon weight was measured, and the numbers
of polyps were macroscopically assessed individually. The colons
were then fixed in 10% formaldehyde and analyzed after staining
with hematoxylin and eosin. MCs were stained as reported
using toluidine blue (Tanaka et al., 2003). CD117 staining
was conducted by using immunohistochemistry as described
procedures (Xuan et al., 2014). NF-κB p65 and phospho-NF-κB
p65 expression in colon tissues was examined by Western blotting
as described above.
Quantification of mMCP-1, TNF-α, and
IL-6 in Serum or in Colon Tissues
To quantify the mMCP-1, TNF-α, and IL-6 in colon tissues,
interstitial liquid was prepared as reported (Baronzio et al., 2012).
Every 100 mg tissue sample was cut into small pieces in 400 µL
ice-cold normal saline and incubated on ice for 5 min. The
mMCP-1 concentrations in interstitial liquid and in serum, and
the TNF-α and IL-6 concentrations in interstitial liquid were
measured using ELISA kits (eBioscience, San Diego, CA, USA)
according to the manufacturer’s instructions.
Flow Cytometry Analysis (FACS) of the
Infiltrated Cells in Colon Tissues
Intraepithelial lymphocytes (IEL) and Lamina propria
lymphocytes (LPL) were prepared as previously described
(Davies and Parrott, 1981). Isolated cells were stained with FITC-
conjugated anti-mouse CD45, PE.Cy7-conjugated anti-mouse
CD11b, and APC-conjugated anti-mouse Gr1 antibodies. Data
were acquired in LSR-II (BD Biosciences, Mountain View, CA,
USA) and analyzed by using FlowJo software (Tree Star, Ashland,
OR, USA). The analysis was based on the gating of CD45-positive
cells.
Investigation of Vam3 on CD11b+Gr1+
Cell Recruitment
Male C57BL/6 mice, 8–10 weeks, were randomly divided into
three groups (n = 3): the naive control group was pretreated
with the vehicle control (0.1% Tween 80 in distilled water)
and intraperitoneally injected with 0.5 mL DMEM medium;
the mMCP-1 group was pretreated with the vehicle control
and intraperitoneally injected with 10 ng recombinant mMCP-
1 diluted into 0.5 mL DMEM medium; the Vam3 group was
pretreated with 50 mg/kg Vam3 and intraperitoneally injected
with 10 ng recombinant mMCP-1 diluted into 0.5 mL DMEM
medium. Cells in peritoneal cavity were collected and counted
22 h after the mMCP-1 injection. Isolated cells were stained with
FITC-conjugated anti-mouse CD45, PE.Cy7-conjugated anti-
mouse CD11b, and APC-conjugated anti-mouse Gr1 antibodies
for FACS. All procedures involving mice (see Isolation of
Peritoneal Macrophages, Induction of CRC and Treatment
with Vam3, and Investigation of Vam3 on CD11b+Gr1+ Cell
Recruitment) were approved by the Institutional Animal Care
and Use Committee at the Cancer hospital, Chinese Academy of
Medical Sciences.
Statistical Analysis
All statistical analysis were performed using the GraphPad
Prism5 program. The statistical analysis was performed using
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one-way ANOVA to determine difference between the groups.
Results were expressed as the means ± SD. A p-value of 0.05 or
less was considered statistically significant.
RESULTS
Vam3 Inhibited the Mast Cell
Degranulation and TNF-α Production
The chemical structure and 1H-NMR spectra of Vam3 was
provided in Figures 1A,B, respectively. To test the dose-
effect of Vam3 on MC degranulation and cytokine production,
1, 2.5, 5, or 10 µM Vam3 was added to the cell culture
medium. The concentration of 1 µM Vam3 showed little effect
(data not shown). Therefore, we chose at least 2.5 µM Vam3
for the following work. The cell viability of RBL-2H3, fresh
isolated peritoneal macrophages, and RAW264.7 cells was not
affected when all these cells were treated with Vam3 (1, 2.5,
or 5 µM) for 24 h (Figures 2A–C; Supplementary Figure S1).
No significant cytotoxicity was observed after incubation with
5 µM Vam3 for up to 48 h (Figures 2D–F; Supplementary
Figure S1). However, 10 µM Vam3 reduced the cell viability
of RBL-2H3 cells to 81.71 ± 3.28% of control (p < 0.01;
Figure 2A). Therefore, 2.5 and 5µM were selected for the present
study.
RBL-2H3 cells have been used as a model of intestinal mucosal
MCs (Lee et al., 2010; Thrasher et al., 2013). The cells display
properties of the intestinal mucosal MCs and share similarities
in granule biochemistry with mucosal MCs, such as RMCP-II
(Seldin et al., 1985). Therefore, in the present study, we used
RBL-2H3 cells as an in vitro model of mucosal MCs. Since
mucosal MCs are mainly reside within the intestinal mucosa
where they are readily exposed to the microbial products, we used
DNP-BSA plus LPS-induced degranulation in RBL-2H3 cells as a
preliminary screening method to investigate the effects of Vam3
on MC degranulation. Compared with the cells stimulated with
DNP-BSA plus LPS, pretreatment with 2.5 and 5 µM Vam3
reduced β-HEX release from an average of 35.21 ± 3.05 to
30.44 ± 3.37% (p = 0.023) and 26.61 ± 1.90% (p < 0.01),
respectively (Figure 3A). However, the levels of β-HEX release
were still higher in the Vam3-treated groups than baseline
(5.46± 2.54%).
We then determined the effects of Vam3 on TNF-α release,
the main preformed inflammatory cytokine in MCs. The TNF-α
production in RBL-2H3 cells stimulated with DNP-BSA plus LPS
was 110.37 ± 9.85 pg/mL. When the cells were pretreated with
2.5 and 5 µM Vam3 for 2 h, TNF-α production was reduced
to 85.77 ± 11.19 pg/mL (p = 0.05) and 76.13 ± 11.55 pg/mL
(p < 0.01), respectively (Figure 3B), but not to baseline level
(43.63 ± 8.90 pg/mL). These data suggested that pretreatment
with Vam3 could inhibit MC degranulation.
Mast cells could produce pro-inflammatory cytokines, such as
TNF-α, in response to LPS without degranulation occurring. So
we further investigated the effects of Vam3 on TNF-α production
in LPS-stimulated RBL-2H3 cells. Compared with the cells
stimulated with LPS alone, pretreatment with 2.5 and 5µM Vam3
reduced the relative mRNA levels of TNF-α from an average
of 2.32 ± 0.04 to 2.09 ± 0.12 (p = 0.044) and 2.06 ± 0.08
(p = 0.025), respectively (Figure 3C), and reduced the protein
levels of TNF-α from an average of 130.63 ± 6.49 pg/mL to
106.17 ± 5.79 pg/mL (p = 0.022) and 92.20 ± 3.05 pg/mL
(p < 0.01), respectively (Figure 3D). However, the mRNA and
protein levels of TNF-α in the Vam3-treated groups were still
higher than baseline. These data suggested that pretreatment with
Vam3 could inhibit LPS-stimulated TNF-α production in MCs
unrelated to degranulation.
FIGURE 1 | (A) Chemical structure of compound Vam3. (B) Typical 1H-NMR spectra of compound Vam3.
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FIGURE 2 | Effects of Vam3 on the viability of RBL-2H3, peritoneal macrophages and RAW264.7 cells. RBL-2H3 (A), peritoneal macrophages (B), and
RAW264.7 (C) plated on 96-well plates were treated with Vam3 (0, 1, 2.5, 5, or 10 µM) for 24 h. RBL-2H3 (D), peritoneal macrophages (E), and RAW264.7 (F) were
treated with Vam3 (0 or 5 µM) for 0–48 h. Cell viability was assessed using the MTT assay and expressed as percentage of controls that were cultured in the
absence of Vam3. ∗∗p < 0.01 compared with the cells cultured in the absence of Vam3.
Vam3 Inhibited TNF-α and IL-6
Production from Macrophages
Primary peritoneal macrophages are a common source of
macrophages for various in vitro studies, including stimulation
with TLR ligands. One advantage in using peritoneal
macrophages is their relative ease of isolation. LPS binds to
CD14/TLR4 complex on mouse peritoneal macrophages and
stimulates several inflammatory cytokine production, including
TNF-α and IL-6 (Akashi et al., 2000). At the site of intestinal
inflammation, some intestinal macrophages also express relevant
levels of TLR4 and CD14. They produce larger amounts of pro-
inflammatory cytokines, such as TNF-α and IL-6, in response to
commensal bacteria (Kamada et al., 2008; Yoshioka et al., 2009).
Moreover, peritoneal macrophages has been used in colitis and
CRC-related studies (Zhao et al., 2014; Yang et al., 2016). Lamina
propria macrophages are constantly exposed to microbial
products and are a major source of pro-inflammatory cytokines,
such as TNF-α and IL-6, in the tumor microenvironment (Terzic
et al., 2010). So we further investigated the effects of Vam3
on TNF-α and IL-6 production in LPS-stimulated peritoneal
macrophages. Compared with the cells stimulated with LPS
alone, pretreatment with 5 µM Vam3 reduced the relative
mRNA levels of TNF-α from an average of 3.96 ± 0.59 to
2.40 ± 0.13 (p < 0.01; Figure 4A). Pretreatment with 2.5 and
5µM Vam3 reduced the protein levels of TNF-α from an average
of 1268.02 ± 25.82 pg/mL to 964.01 ± 119.39 pg/mL (p = 0.032)
and 718.88 ± 129.13 pg/mL (p < 0.01), respectively (Figure 4B).
Meanwhile, when the cells were pretreated with 2.5 and 5 µM
Vam3 for 2 h, the relative mRNA levels of IL-6 decreased from an
average of 2.42± 0.01 to 2.24± 0.05 (p= 0.038) and 2.06± 0.02
(p < 0.01), respectively (Figure 4C), and the protein levels
of IL-6 decreased from an average of 1393.46 ± 30.55 pg/mL
to 1242.89 ± 64.33 pg/mL (p = 0.038) and 1056.01 ± 71.28
(p < 0.01), respectively (Figure 4D). However, the mRNA
and protein levels of TNF-α and IL-6 in the Vam3-treated
groups were still higher than baseline. These data suggested that
pretreatment with Vam3 could inhibit LPS-stimulated cytokine
production in macrophages.
Vam3 Inhibited CRC Development
The CRC murine model was induced by intraperitoneal injection
with procarcinogen AOM followed by one cycle of DSS exposure.
Four weeks after DSS withdrawal, the mice were treated
with Vam3, DSCG, and vehicle for 2 weeks (Figure 5A).
All of the mice developed colon tumors 14 weeks after DSS
withdrawal. However, Vam3 and DSCG treatment reduced
total tumor numbers from an average of 6.50 ± 2.07/mice in
the vehicle-treated mice to 3.40 ± 1.58/mice (p < 0.01) and
3.20 ± 2.49/mice (p = 0.018), respectively (Figures 5B,C).
Treatment with Vam3 and DSCG reduced colon weight from
an average of 0.48 ± 0.03 g to 0.38 ± 0.02 g (p = 0.050) and
0.35 ± 0.02 g (p = 0.010), respectively (Figure 5D). The effect
of Vam3 was not different from that of DSCG in Figures 5C,D
(p > 0.05). Histologically, the vehicle-treated mice showed more
destruction of the colonic epithelium, a thicker muscularis layer
and adenocarcinoma development. However, the structure of
colonic epithelium was improved in the Vam3 and DSCG-
treated mice (Figure 5E). These results collectively indicated that
Vam3 treatment could inhibit CRC development in the murine
model.
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FIGURE 3 | Effects of Vam3 on MC degranulation and on inflammatory
cytokine production. (A,B) RBL-2H3 cells were sensitized with DNP-specific
IgE for 24 h and then treated with Vam3 (0, 2.5, or 5 µM) for 2 h followed by
adding 1 µg/mL LPS for 48 h. To test degranulation, the cells were stimulated
with 500 ng/mL DNP-BSA for 30 min. β-HEX release was measured (A) and
TNF-α production was quantified by ELISA (B). (C,D) RBL-2H3 cells were
pretreated with Vam3 (0, 2.5, or 5 µM) for 2 h followed by adding 1 µg/mL
LPS for 6 h (C) or for 24 h (D). The production of TNF-α was determined by
real-time qPCR (C) and ELISA (D). #p < 0.05, ##p < 0.01 compared with
respective control; ∗p < 0.05, ∗∗p < 0.01 compared with the DNP-BSA plus
LPS-stimulated group (A,B) or the LPS-stimulated group (C,D).
Vam3 Inhibited the Mast Cell Infiltration
and Attenuated Cytokine Production In
vivo
As Vam3 could inhibit RBL-2H3 cell degranulation and decrease
cytokine production in RBL-2H3 cells and macrophages, we
hypothesized that the inhibitory effect of Vam3 on CRC
development may be due to its inhibition on MC degranulation
and cytokine production. As shown in Figures 6A,B, the
numbers of toluidine blue-stained MCs were reduced in the
Vam3 (p = 0.037) and DSCG (p = 0.018)-treated relative to
the vehicle-treated mice. We then stained the colon tissues with
antibody against CD117. CD117 is an early marker for MC
precursors and expressed throughout their lifetime (Hodges et al.,
2012). The numbers of CD117-positive cells were also reduced
in the Vam3 (p = 0.050) and DSCG (p = 0.017)-treated relative
to the vehicle-treated mice (Figures 6C,D). The effect of Vam3
was not different from that of DSCG in reducing MC infiltration
(p> 0.05).
Interstitial fluid is the physical and biochemical micro-
environment of the tumor cells. Post-translational modifications
may occur in interstitial fluid. Studies highlight the importance
of quantification of substances in the interstitial fluid (Garvin
and Dabrosin, 2003; Iversen and Wiig, 2005). Garvin and
Dabrosin (2003) showed that intracellular levels of vascular
endothelial growth factor (VEGF) were increased by tamoxifen.
FIGURE 4 | Effects of Vam3 on inflammatory cytokine production in
LPS-stimulated peritoneal macrophages. (A,B) Peritoneal macrophages
were pretreated with Vam3 (0, 2.5, or 5 µM) for 2 h followed by adding
1 µg/mL LPS for 6 h (A) or for 24 h (B). The production of TNF-α was
determined by real-time qPCR (A) and ELISA (B). (C,D) Similar experimental
design to (A) and (B). The production of IL-6 was determined by real-time
qPCR (C) and ELISA (D). #p < 0.05, ##p < 0.01 compared with respective
control; ∗p < 0.05, ∗∗p < 0.01 compared with the LPS-stimulated group.
However, tamoxifen treatment decreased secretion of VEGF into
extracellular phase and decreased angiogenesis in vivo (Garvin
and Dabrosin, 2003). Therefore, it is important to monitor
biomolecules in the compartment where they are biologically
active. In the present study, mMCP-1, TNF-α, and IL-6 levels
were quantified in interstitial liquid.
The mMCP-1 is predominantly expressed by intestinal
mucosal MCs. After activation and degranulation of the mucosal
MCs, mMCP-1 is released from mucosal MCs. Treatment with
Vam3 and DSCG reduced interstitial liquid mMCP-1 levels
from an average of 4266.94 ± 329.48 pg/mL in the vehicle-
treated mice to 2433.57 ± 896.16 pg/mL (p = 0.050) and
2098.89 ± 1559.16 pg/mL (p = 0.016), respectively (Figure 6E).
The effect of Vam3 was not different from that of DSCG
in Figure 6E (p > 0.05). The mMCP-1 levels in serum did
not decrease significantly after Vam3 treatment (Figure 6F).
However, as mentioned above, it is important to monitor
biomolecules in the compartment where they are biologically
active, such as interstitial fluid. These data indicated that Vam3
treatment inhibited MC infiltration and activation in vivo.
TNF-α and IL-6, expressed in the tumor microenvironment,
are important for the development of inflammation-associated
intestinal tumorigenesis. Treatment with Vam3 reduced TNF-α
levels from an average of 36.65 ± 8.80 pg/mL in the vehicle-
treated mice to 19.61 ± 3.71 pg/mL (p < 0.01; Figure 6G).
Meanwhile, the mice treated with Vam3 revealed a lower IL-6
level, averaging 18.37 ± 13.33 pg/mL, than the mice treated with
vehicle (52.10 ± 40.60 pg/mL) (p = 0.034) (Figure 6H). These
results collectively indicated that Vam3 treatment could inhibit
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FIGURE 5 | Effects of Vam3 on CRC development in murine model. (A) Schematic diagram of the experimental design. CRC was induced by AOM
(12.5 mg/kg) plus DSS (2.5%) in male C57BL/6 mice. Mice were treated with either vehicle, Vam3 (50 mg/kg) or DSCG (100 mg/kg) by oral gavage for 2 weeks.
(B) Macroscopic appearance of colon tissues. (C) Total tumor numbers. (D) Colon weight measurement. (E) Representative hematoxylin and eosin sections of colon
tissues (100×). n = 5–9 per group. ##p < 0.01 compared with the control group. ∗p < 0.05, ∗∗p < 0.01 compared with the AOM plus DSS-induced group.
the MC infiltration and degranulation, and attenuated cytokine
production in vivo.
Vam3 Inhibited CD11b+Gr1+ Cell
Infiltration through Suppression of MC
Degranulation
CD11b+Gr1+ cells were reported to be the immunosuppressive
cell population in the tumor microenvironment that favors
tumor growth and could suppress T cell activity (Wesolowski
et al., 2013). mMCP-1 released from mucosal MCs could induce
CD11b+Gr1+ cell accumulation (Xu et al., 2015). We then
determined the effects of Vam3 treatment on CD11b+Gr1+
cell infiltration by FACS. The percentage and numbers of
CD11b+Gr1+ cells in both IEL and LPL were reduced in the
Vam3 and DSCG-treated relative to the vehicle-treated mice
(p < 0.05 for all; Figures 7A,B). The effect of Vam3 was not
different from that of DSCG (p> 0.05).
To test whether Vam3 may directly inhibit CD11b+Gr1+
cell infiltration, mice were treated with Vam3 and recombinant
mMCP-1 was injected into mouse peritoneal cavity, where no
mucosal MCs reside. Consistent with previous study (Xu et al.,
2015), the CD11b+Gr1+ cells in the peritoneal cavity increased
significantly in the mice that received mMCP-1 (p < 0.01).
However, there were no significant differences in CD11b+Gr1+
cell numbers between the vehicle and Vam3-treated mice that
received mMCP-1 (p > 0.05; Figure 7C). These results indicated
that Vam3 treatment did not directly inhibit CD11b+Gr1+ cell
infiltration. It is most likely that Vam3 inhibited CD11b+Gr1+
cell infiltration through suppression of MC degranulation.
Vam3 Inhibited NF-κB Activation
NF-κB plays a central role in DNP-BSA plus LPS-induced
MC degranulation and in LPS-induced cytokine production
in MCs and macrophages. In the NF-κB signaling cascade,
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FIGURE 6 | Effects of Vam3 on MC infiltration and on cytokine production in colon tissues. (A) MCs stained by toluidine blue (400×). (B) Numbers of
toluidine blue-stained MCs. (C) Immunohistochemical staining for CD117 (200×). (D) Numbers of CD117-positive cells. (E,F) mMCP-1 levels in interstitial fluid (E)
and in serum (F) determined by ELISA. (G,H) TNF-α and IL-6 levels in colon tissues determined by ELISA. n = 5–9 per group. #p < 0.05, ##p < 0.01 compared with
the control group. ∗p < 0.05, ∗∗p < 0.01 compared with the AOM plus DSS-induced group.
phosphorylation of p65 at the serine 536 position is required
for nuclear translocation (Maguire et al., 2015). Therefore, to
determine whether Vam3 exhibited its effect via the NF-κB
pathway, expression of NF-κB p65 and phospho-NF-κB p65 were
determined in the RBL-2H3 cells, peritoneal macrophages and
colon tissues. Compared with the RBL-2H3 cells stimulated with
LPS alone, pretreatment with 5 µM Vam3 reduced the relative
phospho-NF-κB p65 expression from an average of 0.57 ± 0.02
to 0.41 ± 0.02 (p < 0.01; Figures 8A,B). In a similar pattern,
LPS significantly increased phospho-NF-κB p65 expression in
peritoneal macrophages (p < 0.01) whereas Vam3 pretreatment
at 2.5 µM (p = 0.044) and 5 µM (p < 0.01) reduced this
change (Figures 8C,D). Consistent with the in vitro studies
above, treatment with Vam3 reduced relative phospho-NF-κB
p65 expression in colon tissues from an average of 0.77 ± 0.20
to 0.58 ± 0.08 (p = 0.025; Figures 8E,F; Supplementary
Figure S2). However, NF-κB p65 levels were not changed in LPS-
stimulated RBL-2H3 cells and peritoneal macrophages and in
colon tissues.
In addition, we used an NF-κB-dependent luciferase assay to
further determine the effect of Vam3 on NF-κB activity in LPS-
stimulated RAW264.7 cells. Compared with the cells stimulated
with LPS alone, pretreatment with 2.5 and 5 µM Vam3 reduced
the relative luciferase activity from 700.41 ± 260.86-fold of the
control to 331.59 ± 32.65-fold (p = 0.050) and 263.77 ± 19.06-
fold (p = 0.022) of the control, respectively (Figure 8G). All
these findings indicated that Vam3 treatment inhibited NF-κB
activation.
DISCUSSION
In this study, we investigated the effects of compound Vam3,
a resveratrol dimer with potent anti-inflammatory and anti-
oxidant activities (Li et al., 2006; Shi et al., 2012), on colitis-
associated colon carcinogenesis. Pretreatment with Vam3 could
inhibit DNP-BSA plus LPS-induced RBL-2H3 cell degranulation
and decrease cytokine production in LPS-stimulated RBL-2H3
cells and peritoneal macrophages. In the AOM plus DSS-
induced CRC murine model, the Vam3-treated mice had less
tumor numbers than the vehicle-treated mice. Expression of
phospho-NF-κB p65, production of inflammatory cytokines, and
infiltration of MCs and CD11b+Gr1+ cells were attenuated
in the intestines of the Vam3-treated mice compared to
the vehicle-treated mice. These data demonstrated that Vam3
treatment inhibited CRC development and this effect was
likely associated with its inhibition on NF-κB signaling
pathway.
Many studies have documented the critical link between
inflammation and the development of colon cancer (Kraus
and Arber, 2009; Terzic et al., 2010). The microbiota directly
and indirectly affects the development and maintenance of
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FIGURE 7 | Effects of Vam3 on CD11b+Gr1+ cell infiltration. (A) Representative FACS of CD11b+Gr1+ cells in IEL and LPL of AOM plus DSS-induced CRC
murine model. (B) The numbers of CD11b+Gr1+ cells in IEL and LPL of AOM plus DSS-induced CRC murine model. (C) The mice were pretreated with Vam3 or
vehicle before intraperitoneally injection with recombinant mMCP-1 or DMEM medium as described in section “Materials and Methods.” Twenty-two hours after the
mMCP-1 injection, cells infiltrated into the peritoneal cavity were collected using 5 mL of DMEM medium. The numbers of CD11b+Gr1+ cells in each group were
determined by FACS. n = 3–9 per group. #p < 0.05, ##p < 0.01 compared with the control group. ∗p < 0.05 compared with the AOM plus DSS-induced group.
inflammation, which is the hallmark of cancer (Kostic et al., 2013;
Dzutsev et al., 2015). Human intestine harbors over 100 trillion
bacteria, and colon is the most densely populated intestinal
region for bacteria (Sears and Garrett, 2014). Involvement
of commensal bacteria and its components with strong
immunoactivating properties, such as LPS, has been suggested
in the histopathology of colon cancer (Tlaskalova-Hogenova
et al., 2004; Collins et al., 2011; Sears and Garrett, 2014). Altered
epithelial barrier function induces the translocation of luminal
antigens, such as LPS, from the gut lumen into the bowel wall,
which leads to immune cell activation and cytokine production
(Chichlowski and Hale, 2008; Neurath, 2014). LPS has been
suggested to have no effect on MC degranulation. However,
recent studies have shown that prolonged treatment with LPS
resulted in enhancement of MC degranulation following IgE-
receptor cross-linking (Saluja et al., 2012; Yang et al., 2012).
Intestinal MCs activation through FcεRI may play a role in the
pathogenesis of IBD. It was reported that treatment with the
anti-IgE antibody could reduce the expression of MC-mediated
inflammatory factors in DSS-induced colitis (Kang et al., 2006).
However, the mechanisms of MC degranulation in CRC remain
largely unclear. IgE/Ag-activated bone marrow-derived MCs
(BMMCs) was used by Danelli et al. (2015a) to study MC
degranulation on colon tumor development. The results showed
that IgE/Ag-activated BMMCs not only had the potential to
induce MDSCs recruitment, but also contribute to the acquisition
of suppressive functions by MDSCs (Danelli et al., 2015a).
Mucosal MCs predominantly localize to the mucosal
epithelium and lamina propria where they are readily exposed
to microbial products. RBL-2H3 cells have characteristics of
mucosal MCs (Barsumian et al., 1981). Therefore, in this study,
we used DNP-BSA plus LPS-induced degranulation in RBL-2H3
cells as a preliminary screening method to investigate the effects
of Vam3 on MC degranulation. Activated MCs degranulate
and release preformed mediators such as histamine, neutral
proteases, proteoglycans, and some cytokines, such as TNF-α.
Among the preformed mediators, β-HEX is a marker of MC
degranulation (Fukuishi et al., 2014). The present study showed
that pretreatment with Vam3 could inhibit DNP-BSA plus
LPS-induced β-HEX release in RBL-2H3 cells. TNF-α is a
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FIGURE 8 | Effects of Vam3 on NF-κB activation. (A,B) RBL-2H3 cells were pretreated with Vam3 (0, 2.5, or 5 µM) for 2 h followed by adding 1 µg/mL LPS for
12 h. NF-κB p65 and phospho-NF-κB p65 expression was examined by Western blotting (A), and quantification of the NF-κB p65 and phospho-NF-κB p65
expression was performed by densitometric analysis of the blots (B). (C,D) Similar experimental design to (A) and (B) using peritoneal macrophages. (E,F) Colon
tissues from each group were used for NF-κB p65 and phospho-NF-κB p65 expression measurement using Western blotting (n = 9 per group). (G) RAW264.7 cells
were transiently transfected with NF-κB luciferase plasmids. Transfected cells were pretreated with Vam3 (0, 2.5, or 5 µM) for 2 h followed by adding 1 µg/mL LPS
for 24 h. Cells were lysed and the lysates were analyzed by use of a luciferase assay system. #p < 0.05, ##p < 0.01 compared with the control group. ∗p < 0.05,
∗∗p < 0.01 compared with the LPS-stimulated group or the AOM plus DSS-induced group.
FIGURE 9 | Proposed model for Vam3 inhibiting colitis-related
tumorigenesis.
key pro-inflammatory cytokine involved in the development
of CRC (Trejo et al., 2001; Kraus and Arber, 2009). MCs are
the only cell type capable of storing pre-synthesized TNF-α
and have been suggested as an important source for TNF-α
in IBD (Gounaris et al., 2007; Kalesnikoff and Galli, 2008).
The release of TNF-α in DNP-BSA plus LPS-induced RBL-
2H3 cells was attenuated by Vam3 pretreatment. MCs could
produce pro-inflammatory cytokines in response to LPS,
without degranulation occurring. The release of TNF-α was also
attenuated by Vam3 pretreatment in LPS-induced RBL-2H3
cells. Most tumor-promoting cytokines, such as TNF-α and IL-6
are produced by lamina propria macrophages and dendritic
cells (DC) during early states of CRC development (Terzic et al.,
2010). Vam3 pretreatment significantly inhibited the release of
TNF-α and IL-6 in LPS-induced peritoneal macrophages.
Acute toxicity tests in mice showed that the maximal tolerance
dose of Vam3 was greater than 4 g/kg body weight. The growth
and general behavior of the animals appeared normal and
no abnormality was observed in major organs (unpublished
data). Previously we found that oral administration of Vam3
at about 50 mg/kg inhibited inflammatory cell recruitment,
cytokine production and NF-κB activation in ovalbumin (OVA)-
induced asthma murine model (unpublished data), and showed
anti-oxidative effect on cigarette smoke-induced damage (Shi
et al., 2012). Therefore, a dosage of 50 mg/kg was used in
the present study. Vam3 treatment at 50 mg/kg not only
reduced MC infiltration and degranulation but also reduced
the production of TNF-α and IL-6 in an AOM plus DSS-
induced CRC murine model. These results indicated that
Vam3 treatment attenuated CRC development probably by
inhibiting MC degranulation and cytokine release from MCs and
macrophages.
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Myeloid-derived suppressor cells are a heterogeneous
population of immature myeloid cells at different stages of cell
differentiation and defined as CD11b+Gr1+ in mice. MDSCs
are responsible for T cell suppression and the formation
of the immunosuppressive tumor microenvironment that
favors tumor growth. Recent studies highlight the importance
of the bidirectional axis between MDSCs and MCs in
creating tumor-inflammatory and tumor-immunosuppressive
microenvironments (Danelli et al., 2015b). Our current study
found that mMCP-1 released from mucosal MCs induced
CD11b+Gr1+ cell accumulation and further amplified the
potential of CD11b+Gr1+ cells to enhance tumor cell
proliferation and inhibit T cell activation (Xu et al., 2015). As
Vam3 could attenuate MC infiltration and degranulation, we
then determined the effects of Vam3 on MDSC accumulation.
As expected, the percentage and numbers of CD11b+Gr1+ cells
decreased in the colon tissues of the Vam3 treatment group.
However, Vam3 treatment did not directly inhibit mMCP-1-
induced CD11b+Gr1+ cell infiltration in vivo. It is most likely
that Vam3 inhibited CD11b+Gr1+ cell infiltration through
suppression of MC degranulation.
Aberrant or constitutive NF-κB activation has been observed
in many cancers including CRC. Greten et al. (2004) showed that
specific inactivation of the IKK/NF-κB pathway in myeloid cells
can attenuate formation of inflammation-associated tumors in an
AOM plus DSS-induced CRC murine model. NF-κB activation in
premalignant cells induce genes that stimulate cell proliferation
and survival. NF-κB also plays an essential role in the production
of chemokine and cytokine that sustain tumor-associated
inflammation (Grivennikov et al., 2010). LPS recognition by
TLR4/MD2/CD14 initiates the intracellular signaling cascade
in a MyD88-dependant or MyD88-independent manner. This
finally results in the activation of a series of signaling
events, such as NF-κB, that potentiate the production of
inflammatory mediators. Recent studies showed that activation
of the TLR4/Myd88/NF-κB pathway is crucial for LPS-induced
regulation of Ca2+ mobilization and MC degranulation (Yang
et al., 2012). Since NF-κB activation is involved in LPS
plus DNP-BSA-induced MC degranulation and LPS-induced
cytokine release, we hypothesized that the inhibitory effect
of Vam3 on CRC development might be related to NF-κB
inhibition. In our study, we found that Vam3 administration
inhibited the phosphorylation of NF-κB p65 in colon tissues.
Furthermore, pretreatment with Vam3 decreased phospho-
NF-κB p65 levels in LPS-stimulated peritoneal macrophages
and RBL-2H3 cells, and decreased NF-κB-luciferase activity
in LPS-stimulated RAW264.7 cells. These findings suggest
that the effects of Vam3 were at least in part mediated
by inhibiting the NF-kB pathway. The exact mechanism of
how Vam3 inhibits NF-κB activation will require further
investigations.
In summary, our results showed that administration of Vam3
could attenuate the CRC development in an AOM plus DSS-
induced CRC murine model. This effect may be due to its
inhibition on NF-κB signaling pathway in MCs and macrophages
of the inflamed intestines (Figure 9). Vam3 might be a potential
prophylactic agent for CRC therapy.
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